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Introduction: A subset of lung cancers harbors an EML4-ALK
(echinoderm microtubule-associated protein-like 4-anaplastic lym-
phoma kinase) gene fusion, and detecting this subset may hold
therapeutic implications. Many prior studies used fluorescence in
situ hybridization (FISH) analysis for this detection, but FISH may
have disadvantages including signal decay and dark-field examina-
tion that may obscure tissue architecture. In this study, we explored
the potential of the ALK-break-apart chromogenic in situ hybridiza-
tion (CISH) method to detect ALK-rearranged lung cancer.
Methods: We examined 15 lung adenocarcinomas with reverse-
transcriptase polymerase chain reaction-proven EML4-ALK fusion
transcripts and 30 ALK-negative cases. One hundred tumor cells
were evaluated by CISH and FISH for each case, and a detailed
signal profile was recorded and compared.
Results: CISH preserved tissue architecture and cytomorphology con-
siderably and facilitated the signal evaluation using a routine light
microscope. Positive rearrangement signals (splits or isolated 3 sig-
nals) were identified in 13 to 78% (mean SD, 41% 19%) of tumor
cells in the ALK-positive cohort and in 0 to 15% (mean  SD, 6% 
4%) of cells in the ALK-negative cohort. The two groups were best
separated by a cutoff value of 20%, with a sensitivity of 93% and a
specificity of 100%. The only false-negative tumor having only 13%
CISH-positive cells displayed predominantly (76%) isolated 5 signals
unaccompanied by 3 signals. FISH showed largely similar signal
profiles, and the results were completely concordant with CISH.
Conclusions: We have successfully introduced CISH for diagnosing
EML4-ALK-positive lung adenocarcinoma. This method allows simul-
taneous visualization of genetics and tumor cytomorphology and facil-
itates the molecular evaluation and could be applicable in clinical
practice to detect lung cancer that may be responsive to ALK inhibitors.
Key Words: Lung, Adenocarcinoma, Chromogenic in situ hybrid-
ization, Fluorescence in situ hybridization, EML4-ALK, Diagnosis.
(J Thorac Oncol. 2011;6: 1677–1686)
The recent discovery of a fusion gene that joins the echi-noderm microtubule-associated protein-like 4 (EML4)
and anaplastic lymphoma kinase (ALK) in a subset (1–5%) of
non-small cell lung carcinomas (NSCLCs) has added a novel
molecular subtype to the classification scheme for pulmonary
neoplasms.1 The EML4-ALK fusion seems to be formed as
the result of a small inversion within the short arm of
chromosome 2, and the encoded protein, a chimera compris-
ing the N-terminal portion of EML4 and the intracellular
catalytic domain of ALK, is dimerized, leading to consti-
tutive activation.2 To date, a number of fusion variants
have been identified, and KIF5B was discovered to be
another fusion partner of ALK.3 The importance of recogniz-
ing this molecular subtype was highlighted by an interna-
tional phase I/II clinical trial in which the ALK inhibitor
crizotinib (PF02341066) yielded encouraging overall re-
sponse and disease control rates in a cohort of patients with
ALK-rearranged NSCLCs.4 Therefore, an accurate and prac-
tical assay is urgently needed to detect this molecular subset
of lung cancer.
Currently, the methods available for detecting ALK
rearrangement are reverse-transcriptase polymerase chain re-
action (RT-PCR) and fluorescence in situ hybridization
(FISH). ALK immunohistochemistry (IHC), which previ-
ously yielded low sensitivity,3,5 has recently been modified to
yield high detection rates approaching those of RT-PCR and
FISH.3,6 RT-PCR is a single direct test to detect EML4-ALK;
however, it generally requires good quality RNA and a multi-
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plex system7 because of the wide variations in fusion types and
the rare presence of ALK fusion partners other than EML4. Many
prior studies thus favored FISH analysis with the ALK break-
apart probe as a genetic confirmation,4,8,9 because it is easily
applied to formalin-fixed paraffin-embedded tissue, and it covers
multiple ALK fusion variants. Nevertheless, FISH is not without
limitations, including a requirement for highly specialized
equipment, cumbersome manipulation of the fluorescent mi-
croscope, inevitable signal decay after storage, and dark-field
examination that may obscure tissue architecture and cyto-
morphology.6 The latter feature is particularly undesirable in
testing for lung cancers, because they often assume complex
morphologies10 intimately admixed with nonneoplastic cells,
and differentiating tumor cells from the nonneoplastic ele-
ments may be difficult without architectural/cytoplasmic
information.
Chromogenic in situ hybridization (CISH), which was
developed to overcome the aforementioned disadvantages of
FISH, has been used in the diagnostic pathology of other
organ systems with excellent concordance with FISH.11–13
When applied to formalin-fixed paraffin-embedded materials
and examined under the routine bright-field microscope, CISH
enables detection of specific genetic alterations while preserving
tumor architecture and cytomorphology. In this study, we ex-
plore the potential of CISH in diagnosing ALK-positive
NSCLCs in correlation with the results of multiplex RT-PCR for
EML4-ALK and KIF5B-ALK, ALK-break-apart FISH, and a
sensitive ALK IHC newly developed at our laboratory.
Additionally, we aim to provide a detailed description of
the hybridization signal pattern in the tested cases. In most prior
FISH studies, the test results were simply recorded as either
positive or negative in relationship to the preset cutoff value4–
6,8,14; however, this value varied among laboratories including
5%,14 15%,5,8 and 50%,15 as did the definition of FISH-“posi-
tive” cells.4,5,8,14 The number and type of cells to be counted
were not mentioned in many reports.5–8,15 ALK-rearranged
NSCLCs tend to show complex in situ signal patterns on
break-apart probes; therefore, formulating practical diagnostic
criteria requires more than just setting a cutoff value, and studies
that evaluate actual signal profiles should make reliable inter-
pretation possible. Recently, Camidge et al.,9 inspired by Perner
et al.,16 specifically described FISH signal patterns in ALK-
positive NSCLCs and took an important step toward formulating
objective criteria for the in situ assessment. Unfortunately, their
study lacked RT-PCR confirmation or IHC correlation, and the
number of ALK-positive cases was understandably small (13
cases), considering the rarity of this entity in the general popu-
lation. Herein, we add the detailed in situ signal profile of a
further 15 cases of RT-PCR-proven ALK-positive tumors, and
these data should help us better understand the spectrum of
signal patterns and to develop appropriate diagnostic criteria.
MATERIALS AND METHODS
Case Selection
This study was approved by the institutional review
board of the National Cancer Center, Tokyo, Japan. Two
cohorts of primary lung adenocarcinomas were retrieved
from the National Cancer Center archive; all the tumors were
surgically resected, and the histological diagnosis was con-
firmed according to the latest World Health Organization
Classification.10 The first cohort (ALK-positive study group)
consisted of 15 cases of lung adenocarcinoma (P1–P15),
previously confirmed by multiplex RT-PCR (see method
later) to harbor EML4-ALK chimeric transcripts. The second
cohort (ALK-negative control group) consisted of 30 cases of
lung adenocarcinoma (N1–N30), previously shown by mul-
tiplex RT-PCR to lack the EML4-ALK and KIF5B-ALK
fusion genes. Tissue microarray was constructed using dupli-
cate 2.0 mm tissue cores sampled from two different repre-
sentative areas of each tumor (Azumaya, Tokyo).
Reverse-Transcriptase Polymerase Chain
Reaction
Fresh-frozen tumor tissues from each tumor were pow-
dered using CP02 (Covaris, Woburn, MA) and sonicated
using a Covaris S2 (Covaris). Total RNA was extracted using
a mirVana RNA Isolation Kit (Ambion, Foster City, CA), and
complementary DNA was synthesized using MMTV reverse
transcription (Transcriptor First Strand cDNA Synthesis Kit,
Roche Diagnostics, Switzerland). For amplification of the
ALK fusion genes, a mixture of primers covering potential
breakpoints of fusion transcripts (EML4-ALK and KIF5B-
ALK) were used as reported previously.17 The multiplex PCR
conditions were 95°C for 60 seconds, followed by 50 cycles
at 94°C for 15 seconds, 60°C for 30 seconds, and 72°C for 60
seconds.
Chromogenic In Situ Hybridization
The ALK break-apart CISH assay was performed on a
BenchMark XT (Ventana, Tucson, AZ) automated slide pro-
cessing system as described previously.18 Briefly, a custom-
designed ALK break-apart probe set, based on a previous
publication,16 which hybridizes with the neighboring centro-
meric (5 probe labeled with digoxigenin) and telomeric (3
probe labeled with 2,4 dinitrophenyl) sequence of the ALK
gene, was cohybridized after pretreatment. The 5 ALK probe
signal was visualized with alkaline phosphatase (AP)-based
fast blue detection; the AP was subsequently inactivated with
hybridization buffer before the second AP detection step. The
3 ALK probe signal was visualized with AP-based fast red
detection (Figure 1). Tissue sections were counterstained
lightly with diluted hematoxylin II, and nonneoplastic lung
tissue was used as a negative control. One hundred nonover-
lapping tumor cells with hybridization signals were examined
for each case with a light microscope (Olympus BX41,
Olympus, Tokyo, Japan) under a 60 objective lens without
oil immersion, and a detailed signal pattern was recorded for
each cell. Cells lacking any hybridization signal were not
evaluated. The signal in each cell was categorized into one of
the following seven patterns: (1) fused 3/5 only; (2) fused
3/5 and both isolated 3 and 5 (split); (3) both isolated 3
and 5 (split) only; (4) fused 3/5 and isolated 5; (5) fused
3/5 and isolated 3; (6) isolated 5 only; and (7) isolated 3
only (Figure 2). A fused 3/5 signal looked purple or black
due to colocalization of red (3) and blue (5) signals. A split
signal was defined by 5 and 3 probes observed at a distance
more than 1 time the signal size, and signals separated by less
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than that was regarded as fused signals and counted as such. The
CISH-positive cells were defined as having any split signals or
any isolated 3 (red) signals. In addition, we evaluated separate
sets of 50 and 20 tumor cells in a similar manner to determine
how the number of assessed cells affects the test performance.
To verify that a lone 3 (red) signal in ALK-rearranged lung
cancer should be considered equivalent to a true split,4,19,20 we
also evaluated the test performance when limiting the CISH
positivity to split signals and excluding the lone 3 signals.
Fluorescence In Situ Hybridization
FISH used a commercially available break-apart probe
for the ALK gene (Vysis LSI ALK Dual Color, Abbott
Molecular, Abbott Park, IL) in accordance with the manu-
facturer’s instructions. The 5 ALK signal was labeled with
SpectrumGreen (green), and the 3 ALK signal was labeled
with SpectrumOrange (orange) in this probe design. One
hundred nonoverlapping tumor cells with hybridization sig-
nals were examined for each case with a fluorescent micro-
scope (Olympus BX50, Olympus, Tokyo, Japan) under a
100 objective lens with oil immersion, and a detailed signal
pattern was recorded for each cell. Cells lacking any hybrid-
ization signal were not evaluated. The signals were catego-
rized into seven types as in CISH assay. A split signal was
defined by 5 and 3 probes observed at a distance more than
1 time the signal size, and signals separated by less than that
was regarded as fused signals and counted as such. The
FISH-positive cells were defined as having any split signals
or any isolated 3 (orange) signals.
Immunohistochemistry
Four-micrometer-thick sections were deparaffinized,
and heat-induced epitope retrieval was performed with Tar-
geted Retrieval Solution (pH 9.0, Dako, Carpinteria, CA).
The slides were treated with 3% hydrogen peroxide for 20
minutes to block endogenous peroxidase activity, followed
by washing in deionized water for 2 to 3 minutes. The slides
were then incubated with primary antibodies against ALK
protein (1:40, 5A4; Abcam, Cambridge, UK) for 1 hour at
room temperature, and immunoreactions were detected using
the Envision-FLEX and LINKER (Dako). The reactions were
visualized with 3,3-diaminobenzidine, followed by counter-
staining with hematoxylin. Cytoplasmic staining was re-
garded as positive; as staining was diffuse in all the tested
cases, it was graded only by intensity as weak (1), moderate
(2), and strong (3). Appropriate positive and negative
controls were used.
RESULTS
Chromogenic In Situ Hybridization
The distinction between neoplastic and nonneoplastic
elements was easily made by well-preserved tissue architec-
ture and cytoplasmic characteristics. Detailed hybridization
signal profiles are provided in Table 1 and summarized in
Figure 3A, and representative preparations are illustrated in
Figure 4. In situ signals were of variable types, including
fused, split, and isolated patterns, in all the cases examined.
Signal gain (up to eight copies) was common and was
observed with varying degrees in all cases. For ALK-positive
tumors, the proportion of cells with positive CISH signals
was in the range of 13 to 78% (mean  standard deviation
[SD], 41%  19%), and the stochastic “pseudo-positive”
signals for the ALK-negative group were 0 to 15% (mean 
SD, 6%  4%). The two cohorts were best separated, albeit
FIGURE 1. Schematic design of
the break-apart probe set for ana-
plastic large cell lymphoma (ALK)
gene. ALK break-apart probe set
was designed to hybridize with the
neighboring centromeric (5 probe
labeled with digoxigenin) and telo-
meric (3 probe labeled with 2,4
dinitrophenyl) sequence of ALK
gene.
FIGURE 2. Anaplastic lymphoma kinase (ALK) break-apart chromogenic in situ hybridization (CISH) signals were categorized
into the following seven patterns. Blue signal represents 5 region to ALK, and red signal represents 3 to ALK. A, fused 3/5
only; (B) fused 3/5 and split; (C) split only; (D) fused 3/5 and isolated 5; (E) fused 3/5 and isolated 3; (F) isolated 5 only; and
(G) isolated 3 only (ALK-break-apart CISH, 1000).
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TABLE 1. Detailed Signal Profiles of ALK-Break-Apart Chromogenic In Situ Hybridization of Lung
Adenocarcinomas, Along with ALK Immunohistochemical Results
Case
Fused
Only
Fused and
Split
Split
Only
Fused
and 5
Fused
and 3 Lone 5 Lone 3
Positive
Rate IHC
EML4-ALK
P1 58 16 7 3 3 8 5 31% 2
P2 70 10 7 1 9 2 1 27% 2
P3 33 20 14 5 17 0 11 62% 3
P4 11 9 4 56 0 20 0 13% 3
P5 47 24 8 5 8 4 4 44% 3
P6 45 13 10 6 12 1 13 48% 2
P7 49 28 5 6 6 2 4 43% 3
P8 45 2 2 1 33 2 15 52% 2
P9 58 12 5 7 9 6 3 29% 3
P10 57 15 8 5 8 2 5 36% 3
P11 20 2 0 0 62 2 14 78% 2
P12 26 9 0 2 56 0 7 72% 2
P13 65 8 9 4 3 5 6 26% 2
P14 36 17 5 25 3 11 3 28% 1
P15 72 2 4 2 16 1 3 25% 2
EML4-ALK
N1 95 1 0 0 3 0 1 5% 0
N2 80 2 5 5 4 0 4 15% 0
N3 98 0 0 0 2 0 0 2% 0
N4 90 1 3 1 4 0 1 9% 0
N5 92 2 1 0 3 0 2 8% 0
N6 88 0 2 1 6 0 3 11% 0
N7 95 0 0 0 5 0 0 5% 0
N8 88 1 0 1 3 2 5 9% 0
N9 82 2 0 5 3 3 5 10% 0
N10 82 3 6 3 3 0 3 15% 0
N11 86 0 1 3 6 2 2 9% 0
N12 89 2 0 2 6 1 0 8% 0
N13 84 2 0 3 7 4 0 9% 0
N14 82 3 1 6 3 4 1 8% 0
N15 88 1 0 5 6 0 0 7% 0
N16 95 0 0 0 4 0 1 5% 0
N17 99 0 0 1 0 0 0 0% 0
N18 84 0 1 6 5 2 2 8% 0
N19 96 0 1 0 1 1 1 3% 0
N20 95 1 0 2 2 0 0 3% 0
N21 94 1 1 2 2 0 0 4% 0
N22 95 1 0 1 3 0 0 4% 0
N23 87 3 0 3 3 1 3 9% 0
N24 94 0 0 2 4 0 0 4% 0
N25 94 2 1 1 0 2 0 3% 0
N26 94 1 0 2 2 0 1 4% 0
N27 97 0 0 0 3 0 0 3% 0
N28 94 1 0 1 3 0 1 5% 0
N29 92 1 0 3 3 0 1 5% 0
N30 94 1 1 1 1 1 1 4% 0
The positive rate indicates the percentage of cells showing rearrangement-positive signals. It is equal to the total number of cells
exhibiting fused and split signals, split signals only, fused and lone 3 signals, and lone 3 signals only. IHC, ALK immunohistochemistry:
3, strong; 2, moderate; 1, weak; 0, negative.
EML4-ALK, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase.
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narrowly, when the cutoff was set at 20%, with a sensitivity
of 93% and a specificity of 100%. The only false-negative
case (P4) harbored 13% of CISH-positive cells, and a large
number (76%) of tumor cells displayed isolated 5 (blue)
signals without accompanying 3 (red) signals (Figure 5A).
Among the EML4-ALK-positive cases, the proportion of
CISH-positive cells did not seem to correlate with clinico-
pathological parameters, such as age, sex, stage, and tobacco
exposure. When isolated 3 signals (such as those seen in
Figures 2E, G) were excluded from the definition of CISH
positivity, the test sensitivity decreased to 47%, and eight
EML4-ALK-positive cancers were wrongly classified as neg-
FIGURE 3. A, The results of an anaplastic lymphoma kinase (ALK) break-apart chromogenic in situ hybridization assay repre-
sented as a bar chart. Yellow, red, blue, and gray areas represent the percentages of tumor cells with split signals (fused and
split signals or just split signals), isolated 3 signals (fused and red signals or just red signals), isolated 5 signals (fused and
blue signals or just blue signals), and only fused signals, respectively. A combination of the yellow and red areas shows the
rate of rearrangement-positive cells. B, The results of an ALK break-apart fluorescence in situ hybridization assay represented as
a bar chart. Yellow, orange, green, and gray areas represent the percentages of tumor cells with split signals (fused and split
signals or just split signals), isolated 3 signals (fused and orange signals or just orange signals), isolated 5 signals (fused and
green signals or just green signals), and only fused signals, respectively. A combination of the yellow and orange areas shows
the rate of rearrangement-positive rate.
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ative by CISH. The test results based on counting 50 cells
were generally in accordance with those based on 100 cells,
with the sensitivity and specificity retained at 93% and 100%,
respectively. However, the specificity was reduced to 93%
when only 20 tumor cells were evaluated (Table 2).
Fluorescence In Situ Hybridization
Detailed hybridization signal profiles are provided in
Table 3 and summarized in Figure 3B. For ALK-positive
tumors, the proportion of cells with positive FISH signals was
in the range of 3 to 72% (mean  SD, 41%  17%), and the
stochastic “pseudo-positive” signals for the control group
were 1 to 10% (mean  SD, 5%  3%). The two cohorts
were best separated, albeit narrowly, when the cutoff was set
at approximately 15 to 20%, with a sensitivity of 93% and a
specificity of 100%. The only false-negative case (P4) har-
bored 3% of FISH-positive cells, and a large number (75%)
of tumor cells displayed isolated 5 (green) signals without
accompanying 3 (orange) signals (Figure 5B). Among the
EML4-ALK positive cases, the proportion of FISH-positive
FIGURE 4. A, anaplastic lymphoma kinase (ALK) break-apart chromogenic in situ hybridization in an echinoderm microtu-
bule-associated protein-like 4 (EML4)-ALK-positive lung adenocarcinoma (P1) displayed a significant number of rearrange-
ment signals (arrows, split and lone 3 signals, ALK-break-apart CISH, 600). B, EML4-ALK-negative carcinoma (N1) pre-
dominantly showed 3/5 fused signals that looked purple or black due to colocalization of red and blue signals (ALK-
break-apart CISH, 600).
FIGURE 5. A, The only CISH false-negative case (P4) harbored a large number of cells displaying isolated 5 signals unaccom-
panied by 3 signals (ALK-break-apart CISH, 1000). B, This atypical profile was replicated by fluorescence in situ hybridization
(FISH) as predominantly lone 5 green signal pattern (ALK-break-apart FISH, 1000).
TABLE 2. ALK-Break-Apart Chromogenic In Situ
Hybridization Test Performance When Different Numbers of
Tumor Cells Were Evaluated
100 Cells 50 Cells 20 Cells
Sensitivity 93% 93% 93%
Specificity 100% 100% 93%
ALK, anaplastic lymphoma kinase.
Yoshida et al. Journal of Thoracic Oncology • Volume 6, Number 10, October 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer1682
TABLE 3. Detailed Signal Profiles of ALK-Break-Apart Fluorescence In Situ Hybridization of Lung
Adenocarcinomas, Along with ALK Immunohistochemical Results
Case
Fused
Only
Fused and
Split
Split
Only
Fused
and 5
Fused
and 3 Lone 5 Lone 3
Positive
Rate IHC
EML4-ALK
P1 53 29 7 5 2 2 2 40% 2
P2 62 13 5 9 9 1 1 28% 2
P3 23 30 1 11 22 1 12 65% 3
P4 22 1 1 47 1 28 0 3% 3
P5 53 26 6 10 4 1 0 36% 3
P6 50 25 14 1 5 2 3 47% 2
P7 60 23 3 8 6 0 0 32% 3
P8 56 0 0 1 37 1 5 42% 2
P9 37 34 13 4 9 3 0 56% 3
P10 52 28 12 4 3 0 1 44% 3
P11 27 2 0 1 52 0 18 72% 2
P12 67 0 0 1 26 0 6 32% 2
P13 61 13 10 7 2 5 2 27% 2
P14 42 4 2 5 38 0 9 53% 1
P15 61 8 1 4 25 0 1 35% 2
EML4-ALK
N1 96 0 0 3 1 0 0 1% 0
N2 89 4 0 5 1 0 1 6% 0
N3 93 0 1 3 3 0 0 4% 0
N4 97 0 0 0 2 0 1 3% 0
N5 94 0 0 6 0 0 0 0% 0
N6 82 3 3 5 1 3 3 10% 0
N7 94 2 1 2 1 0 0 4% 0
N8 91 4 2 2 0 0 1 7% 0
N9 71 2 0 23 3 1 0 5% 0
N10 81 5 0 5 4 5 0 9% 0
N11 79 5 0 9 5 2 0 10% 0
N12 95 1 1 1 0 2 0 2% 0
N13 93 1 2 1 2 1 0 5% 0
N14 90 2 0 2 4 1 1 7% 0
N15 93 3 0 2 2 0 0 5% 0
N16 97 0 0 1 1 0 1 2% 0
N17 94 1 0 3 1 0 1 3% 0
N18 91 3 0 2 3 0 1 7% 0
N19 86 3 1 5 4 1 0 8% 0
N20 95 1 0 1 3 0 0 4% 0
N21 96 1 0 1 1 0 1 3% 0
N22 93 5 0 0 1 1 0 6% 0
N23 95 0 2 2 1 0 0 3% 0
N24 84 4 2 6 3 0 1 10% 0
N25 94 2 1 0 3 0 0 6% 0
N26 98 0 1 1 0 0 0 1% 0
N27 95 1 0 3 1 0 0 2% 0
N28 95 1 0 0 1 2 1 3% 0
N29 93 3 1 0 2 1 0 6% 0
N30 91 1 1 4 1 0 2 5% 0
The positive rate indicates the percentage of cells showing rearrangement-positive signals. It is equal to the total number of cells
exhibiting fused and split signals, split signals only, fused and lone 3 signals, and lone 3 signals only. IHC, ALK immunohistochemistry;
3, strong; 2, moderate; 1, weak; 0, negative.
EML4-ALK, echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase; IHC, immunohistochemistry.
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cells did not seem to correlate with clinicopathological pa-
rameters, including age, sex, stage, and tobacco exposure.
Correlation between CISH and FISH
The results of CISH and FISH are compared in Table 4.
The test sensitivity and specificity were completely concor-
dant between the two assays. The proposed cutoff value that
best separates two cohorts was also similar, approximately
20% in both modalities. Moreover, the two techniques pro-
vided a largely similar signal profile in each case. For exam-
ple, cases showing predominantly isolated 3 signals with
CISH showed a similar pattern with FISH (cases P8, P11, and
P12). Similarly, case P4 showed predominantly isolated 5
signals with both CISH and FISH; this case was false nega-
tive for ALK rearrangement by both modalities. Differences
in signal patterns were identified in a few cases; this likely
reflects the differences in probe design. For example, P14
showed a significant number of split signals with CISH but
predominantly isolated 3 signals with FISH.
Immunohistochemistry
Immunohistochemical results are summarized in Ta-
bles 1 and 3. All the 15 cases in the EML4-ALK-positive
group were positively labeled for ALK (Figure 6). The
staining intensity was strong in six cases, moderate in eight
cases, and weak in one case. The staining pattern was diffuse
and cytoplasmic, and virtually all the cells in the cores were
labeled. No significant intratumoral staining heterogeneity
was observed; although cells with abundant intracytoplasmic
mucus tended to exhibit weaker staining than those without,
perhaps because cytoplasmic ALK protein is diminished by a
large volume of mucus material. All the 30 cases in the
control group were immunonegative. There was no apparent
correlation between the proportion of CISH- or FISH-positive
cells and the intensity of immunostaining.
DISCUSSION
This study has produced data suggesting CISH as a
promising method to detect ALK rearrangement in EML4-
ALK-positive lung adenocarcinomas. The previously reported
advantages of CISH over FISH11–13 were confirmed as fol-
lows: (1) the morphological indicators of tumor cells were
adequately preserved, which greatly facilitated the overall
evaluation and (2) CISH signals were easily observed under
a routine light microscope without oil immersion. The high
(93%) sensitivity and perfect (100%) specificity of CISH are
totally concordant with those of FISH and indicates its large
potential for future clinical applications.
The difference in the proportion of CISH/FISH-positive
cells between the two groups was relatively modest (41% 
19% versus 6% 4% in CISH; 41% 17% versus 5% 3%
in FISH). The results generally agree with the FISH analysis
by Camidge et al.,9 who showed a range of 22 to 87% for
ALK-positive tumors and up to 11% in ALK-negative tis-
sues. The inherent difficulty associated with in situ hybrid-
ization analysis for EML4-ALK-positive lung cancer was
previously emphasized6,15,17 and may have resulted partly
from this narrow separation. These data highlight the impor-
tance of a quantitative approach in the CISH/FISH analysis
for diagnosing EML4-ALK-positive NSCLC cases. Determin-
ing an appropriate cutoff value is imperative for accurate
assessment, and this figure may vary among laboratories
(20% in this study and 15% in others) depending on actual
test settings. Although the cutoff value was within the range
of 10 to 20% in many studies, it is essential that each
laboratory performs a validation assay with an RT-PCR-
confirmed set of EML4-ALK-positive cases.
Limiting the number of examined cells to 20 reduced
the test accuracy, and our data suggested that at least 50
tumor cells should be evaluated to accurately detect ALK
status. Sixty was also proposed to be a viable cell number for
accurate evaluation.9 We are uncertain whether diagnosis is
facilitated if more than 100 cells are examined, especially
when dealing with a tumor that shows rearrangement signals
in a range on the borderline between positives and negatives
(10–20%). In such cases, we suggest that rather than per-
forming exhaustive repeated counting, it is more practical to
FIGURE 6. Anaplastic lymphoma kinase (ALK) immunohis-
tochemistry diffusely stained all the echinoderm microtu-
bule-associated protein-like 4 (EML4)-ALK-positive lung ade-
nocarcinomas, and it was negative in all the EML4-ALK-
negative cases (A, negative; B, weakly positive; C, moderately
positive; and D, strongly positive. ALK immunohistochemis-
try, 200).
TABLE 4. A Comparison between ALK-Break-Apart
Chromogenic In Situ Hybridization (CISH) and Fluorescence
In Situ Hybridization (FISH)
CISH FISH
Average positive rate
in ALK cases
41% (range: 13–78%) 41% (range: 3–72%)
Average positive rate
in ALK cases
6% (range: 0–15%) 5% (range: 1–10%)
Best cutoff value 20% 15–20%
Sensitivity 93% 93%
Specificity 100% 100%
ALK, anaplastic lymphoma kinase.
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follow a corroborative approach that takes other data into
consideration. In particular, the immunohistochemical
method we have developed and described herein showed
complete concordance with RT-PCR results and may supple-
ment CISH/FISH analysis in difficult cases. The clinicopath-
ological characteristics of EML4-ALK-positive NSCLCs have
also been well documented5,21 and may assist diagnosis in
such cases.
The relatively low rate of rearrangement-positive cells
in EML4-ALK-positive NSCLCs has been a subject of de-
bate.9,16 Perner et al. first observed the focal (50–100%)
nature of the FISH-positive cells in the majority of EML4-
ALK-positive NSCLCs and hypothesized that EML4-ALK
fusion represents an acquired event developed at a late stage
in tumorigenesis, not an oncogenic molecular drive. Camidge
et al., in contrast, ascribed this low positivity rate (22% at
lowest in their series) primarily to a technical artifact because
the intrachromosomal proximity (12 Mb) of the EML4 and
ALK genes produces only a narrow split that is difficult to
resolve by contemporary in situ technology. In addition to
confirming the low rate of positive cells (13–78% in CISH
and 3–72% in FISH), we demonstrated diffuse ALK immu-
noreactivity even in cases harboring only a low percentage of
in situ hybridization-positive cells. The intensity of immuno-
labeling seemed unrelated to the proportion of CISH-positive
cells. Although a previous study showed expression of wild-
type ALK in an EML4-ALK-positive tumor,1 the diffuse
cytoplasmic immunoreactivity in this study seems incompat-
ible with wild-type ALK expression because wild-type ALK
is expected to show membranous subcellular localization.2
Our IHC data, therefore, suggest diffuse distribution of chi-
meric ALK protein in EML4-ALK-positive tumors and indi-
cate that the apparently low rate of rearrangement-positive
cells by in situ hybridization is a technical artifact, not
authentic intratumoral heterogeneity.
We confirmed the widely held view that isolated 3
hybridization signals should be regarded as positive for ALK
rearrangement in the diagnosis of NSCLCs.4,9,19 Disregarding
these signals would have misclassified more than half of the
EML4-ALK-positive cases in our CISH study. The molecular
basis for the loss of the 5 signal is unclear, but it is believed
to represent a deletion spanning a fusion locus.19 Notably, the
first reported EML4-ALK-positive lung cancer did not harbor
a reciprocal ALK-EML4 gene,1 which seems inconsistent with
a proposed simple inversion mechanism and may indicate a
coexisting deletion near the fusion point; the in situ data were
not provided for that case. Deletion associated with translo-
cation has been described in other tumors such as chronic
myelogenous leukemia22 and ERG-rearranged prostate cancer,23
where such a deletion implicates an aggressive clinical course.
The biological significance of the loss of 5 signals in EML4-
ALK-positive lung cancer is yet to be determined. In our study,
there was no evident behavioral difference between the three
cases (P8, P11, and P12) that showed predominant 5 loss and
the remaining 12 ALK-positive cases.
Because the 5 hybridization signal represents the non-
catalytic domain of ALK kinase, isolated 5 signals without
accompanying 3 signals seem to be irrelevant with respect to
EML4-ALK activity and ALK overexpression.9 Lone 5 sig-
nals have thus been disregarded and have not been deemed
positive in any prior studies including a clinical trial.4 Nota-
bly, the only false-negative case (P4) in our series harbored a
large number (76% in CISH and 75% in FISH) of tumor cells
with isolated 5 signals unaccompanied by 3 signals. This
tumor, which harbored a typical variant 1 chimeric EML4-
ALK transcript and was strongly immunopositive for ALK,
occurred in a young patient with light smoking exposure, and
it had a predominantly acinar histology and a focal signet-
ring cell component, characteristic of ALK-rearranged adeno-
carcinoma.5,21 If lone 5 signals should be considered in
isolation as positive evidence of rearrangement without con-
current 3 signals, then the proportion of CISH-positive cells
for the case P4 would be 89% and that for the entire
ALK-positive group would range from 28 to 89%. The
proportion of CISH-positive cells for the ALK-negative
group would range from 1 to 20%, and the two groups would
be differentiated from each other with a new cutoff at ap-
proximately 25%. Nevertheless, because the molecular basis
of the isolated 5 signal is unknown, and because one ALK-
negative case (N9) showed moderate number (23/100) of
cells with lone 5 signals in FISH, we are reluctant to
immediately incorporate such an ad hoc approach into routine
diagnostics. Further study is needed to elucidate the mecha-
nism of lone 5 signals and to determine their value in
CISH/FISH for diagnosing ALK-positive NSCLCs. We rec-
ommend, for the time being, that cases with a predominantly
lone 5 profile should be treated with caution and that the
clinical, histological, and immunohistochemical findings
should be carefully correlated. We recently encountered an-
other FISH-false-negative case (not included in this series)
displaying a similar profile predominated by isolated 5
signals, and we suspect that this may be a recurring pattern of
CISH/FISH false negativity in ALK-rearranged lung cancer.
In conclusion, we have successfully introduced CISH
for diagnosing EML4-ALK-positive lung adenocarcinoma.
This novel method allows simultaneous visualization of ge-
netics and tumor cytomorphology and markedly facilitates
the molecular evaluation. The cutoff value for positivity was
best set at 20% in our series, but each laboratory should
perform a validation series for the clinical application of the
in situ technology. ALK IHC may supplement the CISH/
FISH analysis for difficult cases. Although the proportion
of rearrangement-positive cells may be low in EML4-ALK-
positive tumors, the invariable diffuse ALK immunoreac-
tivity of tumor cells suggested that the apparent low rate
represents a technical artifact and not true intratumoral
genetic heterogeneity. We confirmed that a lone 3 signal
should be treated as equivalent to a split signal and
regarded as positive rearrangement. Predominantly iso-
lated 5 signal may be a recognizable pattern in CISH/
FISH false negativity, and this atypical profile warrants
further investigation.
ACKNOWLEDGMENTS
Supported, in part, by Grant-in-Aid for the Third-Term
Comprehensive 10-Year Strategy for Cancer Control from
the Ministry of Health, Labor and Welfare of Japan (H.T.).
Journal of Thoracic Oncology • Volume 6, Number 10, October 2011 CISH for ALK-Positive Lung Cancer
Copyright © 2011 by the International Association for the Study of Lung Cancer 1685
The authors thank Dr. H. Mano for providing us infor-
mation about the sequence of primers and multiplex PCR
condition. They also thank Mses. Sachiko Miura, Chizu Kina,
Karin Yokozawa, and Mr. Susumu Wakai for superb technical
assistance.
REFERENCES
1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming
EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;
448:561–566.
2. Mano H. Non-solid oncogenes in solid tumors: EML4-ALK fusion
genes in lung cancer. Cancer Sci 2008;99:2349–2355.
3. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion
oncokinase identified by an immunohistochemistry-based diagnostic
system for ALK-positive lung cancer. Clin Cancer Res 2009;15:3143–
3149.
4. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase
inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693–
1703.
5. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic
features characterize ALK-rearranged lung adenocarcinoma in the west-
ern population. Clin Cancer Res 2009;15:5216–5223.
6. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive
antibody allows for the routine detection of ALK-rearranged lung
adenocarcinomas by standard immunohistochemistry. Clin Cancer Res
2010;16:1561–1571.
7. Takeuchi K, Choi YL, Soda M, et al. Multiplex reverse transcription-
PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res
2008;14:6618–6624.
8. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and
outcome of patients with non-small-cell lung cancer who harbor EML4-
ALK. J Clin Oncol 2009;27:4247–4253.
9. Camidge DR, Kono SA, Flacco A, et al. Optimizing the detection of
lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene
rearrangements potentially suitable for ALK inhibitor treatment. Clin
Cancer Res 2010;16:5581–5590.
10. Travis WD, Brambilla E, Muller-Hermelink HK, et al. Pathology and
Genetics: Tumours of the Lung, Pleura, Thymus and Heart. Lyon,
France: IARC Press, 2004.
11. Motoi T, Kumagai A, Tsuji K, et al. Diagnostic utility of dual-color
break-apart chromogenic in situ hybridization for the detection of
rearranged SS18 in formalin-fixed, paraffin-embedded synovial sar-
coma. Hum Pathol 2010;41:1397–1404.
12. Nitta H, Hauss-Wegrzyniak B, Lehrkamp M, et al. Development of auto-
mated brightfield double in situ hybridization (BDISH) application for
HER2 gene and chromosome 17 centromere (CEN 17) for breast carcino-
mas and an assay performance comparison to manual dual color HER2
fluorescence in situ hybridization (FISH). Diagn Pathol 2008;3:41.
13. Garcia-Caballero T, Grabau D, Green AR, et al. Determination of HER2
amplification in primary breast cancer using dual-colour chromogenic in
situ hybridization is comparable to fluorescence in situ hybridization: a
European multicentre study involving 168 specimens. Histopathology
2010;56:472–480.
14. Boland JM, Erdogan S, Vasmatzis G, et al. Anaplastic lymphoma kinase
immunoreactivity correlates with ALK gene rearrangement and tran-
scriptional up-regulation in non-small cell lung carcinomas. Hum Pathol
2009;40:1152–1158.
15. Sakairi Y, Nakajima T, Yasufuku K, et al. EML4-ALK fusion gene
assessment using metastatic lymph node samples obtained by endobron-
chial ultrasound-guided transbronchial needle aspiration. Clin Cancer
Res 2010;16:4938–4945.
16. Perner S, Wagner PL, Demichelis F, et al. EML4-ALK fusion lung
cancer: a rare acquired event. Neoplasia 2008;10:298–302.
17. Yoshida A, Tsuta K, Watanabe SI, et al. Frequent ALK rearrangement
and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring
cell component. Lung Cancer 2011;72:309–315.
18. Nitta H, Zhang W, Kelly BD, et al. Automated brightfield break-apart in
situ hybridization (ba-ISH) application: ALK and MALT1 genes as
models. Methods 2010;52:352–358.
19. Sasaki T, Rodig SJ, Chirieac LR, et al. The biology and treatment of
EML4-ALK non-small cell lung cancer. Eur J Cancer 2010;46:1773–1780.
20. Solomon B, Varella-Garcia M, Camidge DR. ALK gene rearrangements:
a new therapeutic target in a molecularly defined subset of non-small cell
lung cancer. J Thorac Oncol 2009;4:1450–1454.
21. Inamura K, Takeuchi K, Togashi Y, et al. EML4-ALK lung cancers are
characterized by rare other mutations, a TTF-1 cell lineage, an acinar
histology, and young onset. Mod Pathol 2009;22:508–515.
22. Huntly BJ, Reid AG, Bench AJ, et al. Deletions of the derivative
chromosome 9 occur at the time of the Philadelphia translocation and
provide a powerful and independent prognostic indicator in chronic
myeloid leukemia. Blood 2001;98:1732–1738.
23. Perner S, Demichelis F, Beroukhim R, et al. TMPRSS2:ERG fusion-
associated deletions provide insight into the heterogeneity of prostate
cancer. Cancer Res 2006;66:8337–8341.
Yoshida et al. Journal of Thoracic Oncology • Volume 6, Number 10, October 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer1686
